LU91101I2 - Insuline acylee - Google Patents

Insuline acylee

Info

Publication number
LU91101I2
LU91101I2 LU91101C LU91101C LU91101I2 LU 91101 I2 LU91101 I2 LU 91101I2 LU 91101 C LU91101 C LU 91101C LU 91101 C LU91101 C LU 91101C LU 91101 I2 LU91101 I2 LU 91101I2
Authority
LU
Luxembourg
Prior art keywords
amino acid
acid residue
lys
present
cys
Prior art date
Application number
LU91101C
Other languages
English (en)
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26065125&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91101(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DK104493A external-priority patent/DK104493D0/da
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of LU91101I2 publication Critical patent/LU91101I2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/02—Hepadnaviridae, e.g. hepatitis B virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
LU91101C 1993-09-17 2004-09-08 Insuline acylee LU91101I2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK104493A DK104493D0 (da) 1993-09-17 1993-09-17 Hidtil ukendte peptider
US19082994A 1994-02-02 1994-02-02
PCT/DK1994/000347 WO1995007931A1 (en) 1993-09-17 1994-09-16 Acylated insulin

Publications (1)

Publication Number Publication Date
LU91101I2 true LU91101I2 (en) 2004-11-08

Family

ID=26065125

Family Applications (1)

Application Number Title Priority Date Filing Date
LU91101C LU91101I2 (en) 1993-09-17 2004-09-08 Insuline acylee

Country Status (30)

Country Link
US (1) US5750497A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (2) EP0792290B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (3) JP3014764B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR100310122B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1056618C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE204882T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (2) AU682061B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BG (1) BG61611B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR9407508A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2171424C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CZ (1) CZ287945B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (2) DE122004000035I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK0792290T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2163451T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI117055B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR04C0020I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HU217684B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL110977A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LU (1) LU91101I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (1) NL300160I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (3) NO316944B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ273285A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL178466B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT792290E (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RO (1) RO112873B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2164520C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (1) SI0792290T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SK (1) SK282495B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UA (1) UA45321C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO1995007931A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (193)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9316895D0 (en) * 1993-08-13 1993-09-29 Guy S And St Thomas Hospitals Hepatoselective insulin analogues
US6342225B1 (en) 1993-08-13 2002-01-29 Deutshces Wollforschungsinstitut Pharmaceutical active conjugates
US6869930B1 (en) * 1993-09-17 2005-03-22 Novo Nordisk A/S Acylated insulin
US5474978A (en) * 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5504188A (en) * 1994-06-16 1996-04-02 Eli Lilly And Company Preparation of stable zinc insulin analog crystals
DE4437604A1 (de) * 1994-10-21 1996-04-25 Basf Ag Konjugate aus einem Poly- oder Oligopeptid und einer niedermolekularen lipophilen Verbindung
US5646242A (en) * 1994-11-17 1997-07-08 Eli Lilly And Company Selective acylation of epsilon-amino groups
US5693609A (en) * 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
CA2215694A1 (en) * 1995-03-17 1996-09-26 Novo Nordisk A/S Insulin derivatives
US6251856B1 (en) 1995-03-17 2001-06-26 Novo Nordisk A/S Insulin derivatives
US20010041786A1 (en) * 1995-06-07 2001-11-15 Mark L. Brader Stabilized acylated insulin formulations
GB9513967D0 (en) * 1995-07-08 1995-09-06 Univ Leicester Insulin
US6451970B1 (en) 1996-02-21 2002-09-17 Novo Nordisk A/S Peptide derivatives
JP4404380B2 (ja) * 1996-06-20 2010-01-27 ノボ ノルディスク アクティーゼルスカブ ＮａＣｌ含有インスリン製剤
AU3255297A (en) * 1996-07-11 1998-02-09 Novo Nordisk A/S Selective acylation method
US5905140A (en) * 1996-07-11 1999-05-18 Novo Nordisk A/S, Novo Alle Selective acylation method
DE59711533D1 (de) * 1996-07-26 2004-05-27 Aventis Pharma Gmbh Insulinderivate mit erhöhter Zinkbindung
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
US20020025933A1 (en) * 1996-08-30 2002-02-28 Knudsen Liselotte Bjerre GLP-2 derivatives
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US5898067A (en) * 1997-02-07 1999-04-27 Novo Nordisk A/S Crystallization of proteins
IL131796A0 (en) * 1997-03-20 2001-03-19 Novo Nordisk As Zinc free insulin crystals for use in pulmonary compositions
US6043214A (en) * 1997-03-20 2000-03-28 Novo Nordisk A/S Method for producing powder formulation comprising an insulin
US6310038B1 (en) * 1997-03-20 2001-10-30 Novo Nordisk A/S Pulmonary insulin crystals
ZA989644B (en) * 1997-10-24 2000-04-25 Lilly Co Eli Insoluble insulen compositions.
US6444641B1 (en) 1997-10-24 2002-09-03 Eli Lilly Company Fatty acid-acylated insulin analogs
AU747926B2 (en) 1997-10-24 2002-05-30 Eli Lilly And Company Insoluble insulin compositions
CA2308705A1 (en) * 1997-10-24 1999-05-06 Novo Nordisk A/S Aggregates of human insulin derivatives
US6451762B1 (en) 1997-10-24 2002-09-17 Novo Nordisk A/S Aggregates of human insulin derivatives
ZA989744B (en) * 1997-10-31 2000-04-26 Lilly Co Eli Method for administering acylated insulin.
CO4970787A1 (es) 1997-12-23 2000-11-07 Lilly Co Eli Composiciones insolubles de insulina y derivados de insulina que controlan la glucosa sanguinea
EP1396272A1 (en) * 1997-12-23 2004-03-10 Eli Lilly & Company Insoluble Insulin Compositions for Controlling Blood Glucose
WO1999034821A1 (en) * 1998-01-09 1999-07-15 Novo Nordisk A/S Stabilised insulin compositions
JP2002504527A (ja) * 1998-02-27 2002-02-12 ノボ ノルディスク アクティーゼルスカブ 部分的に組織化したミセル様凝集物を形成する２５％を越えるヘリックス成分を有するｇｌｐ−２誘導体
DE19825447A1 (de) * 1998-06-06 1999-12-09 Hoechst Marion Roussel De Gmbh Neue Insulinanaloga mit erhöhter Zinkbildung
AU8029798A (en) * 1998-06-12 2000-01-05 Deutsches Wollforschungsinstitut Insulin analogue
US7169889B1 (en) 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
WO2001072323A2 (en) 2000-03-24 2001-10-04 Genentech, Inc. Use of insulin for the treatment of cartilagenous disorders
WO2001085256A2 (en) * 2000-05-05 2001-11-15 Novo Nordisk A/S Critical illness neuropathy
US7316999B2 (en) 2000-06-02 2008-01-08 Novo Nordisk A/S Glucose dependent release of insulin from glucose sensing insulin derivatives
JP2004502784A (ja) * 2000-07-10 2004-01-29 ビーティージー・インターナショナル・リミテッド インスリン誘導体とその合成
WO2002051428A1 (en) * 2000-12-25 2002-07-04 Shiseido Company, Ltd. Sympathetic-activating perfume composition
US6867183B2 (en) * 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7060675B2 (en) 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
JP2004529160A (ja) * 2001-05-02 2004-09-24 ノボ・ノルデイスク・エー／エス 胆汁酸の製造
US6653492B2 (en) 2001-05-02 2003-11-25 Novo Nordick A/S Preparation of bile acids
US6835802B2 (en) * 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6713452B2 (en) 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828305B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7713932B2 (en) * 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US6906027B2 (en) * 2001-07-05 2005-06-14 Translational Research Ltd. Composition for nasal administration of insulin
US7595172B2 (en) 2001-07-24 2009-09-29 Novo Nordisk A/S Method for making acylated polypeptides
US7238663B2 (en) 2001-08-28 2007-07-03 Eli Lilly And Company Pre-mixes of GLP-1 and basal insulin
US7176278B2 (en) 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
US7196059B2 (en) * 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US6913903B2 (en) * 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7312192B2 (en) * 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7166571B2 (en) * 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
DK1430082T3 (da) 2001-09-07 2010-01-18 Biocon Ltd Fremgangsmåde til syntese af insulinpolypeptid-oligomer-konjugater og proinsulinpolypeptid-oligomerkonjugater samt fremgangsmåde til syntese deraf
EP1444219A1 (en) 2001-10-12 2004-08-11 Novo Nordisk A/S Substituted piperidines and their use for the treatment of diseases related to the histamine h3 receptor
CN1571676A (zh) 2001-10-19 2005-01-26 伊莱利利公司 Glp－1和胰岛素的双相混合物
RU2376379C2 (ru) 2001-11-19 2009-12-20 Ново Нордиск А/С Способ получения инсулиновых соединений
GB0206792D0 (en) 2002-03-22 2002-05-01 Leuven K U Res & Dev Normoglycemia
DE60335797D1 (de) * 2002-05-07 2011-03-03 Novo Nordisk As Lösliche formulierungen, die monomeres insulin und acyliertes insulin enthalten
US7601688B2 (en) 2002-06-13 2009-10-13 Biocon Limited Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
US20040038864A1 (en) * 2002-06-27 2004-02-26 Per Balschmidt Use of dimethyl sulfone as isotonicity agent
MXPA05003002A (es) * 2002-09-25 2005-06-22 Novo Nordisk As Metodo para producir peptidos acilados.
US7273921B2 (en) 2002-09-25 2007-09-25 Novo Nordisk A/S Method for producing acylated peptides
US7411039B2 (en) 2002-10-14 2008-08-12 Novo Nordisk A/S GLP-2 compounds, formulations, and uses thereof
US20040138099A1 (en) * 2002-11-29 2004-07-15 Draeger Eberhard Kurt Insulin administration regimens for the treatment of subjects with diabetes
WO2004085472A1 (en) * 2003-03-27 2004-10-07 Novo Nordisk A/S Method for making human insulin precursors and human insulin
WO2004089896A1 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS
WO2004096266A1 (en) * 2003-05-02 2004-11-11 Novo Nordisk A/S Improved physical stability of insulin formulations
RU2381103C2 (ru) 2003-06-27 2010-02-10 Ново Нордиск А/С Контейнер для жидких фармацевтических композиций с высокими влагозащитными свойствами
JP4463814B2 (ja) * 2003-08-05 2010-05-19 ノボ ノルディスク アクティーゼルスカブ 新規のインスリン誘導体
ES2402592T3 (es) 2003-08-05 2013-05-07 Novo Nordisk A/S Nuevos derivados de insulina
EP1687428A1 (en) 2003-11-14 2006-08-09 Novo Nordisk A/S Processes for making acylated insulin
DK3300721T4 (da) 2003-11-20 2025-03-03 Novo Nordisk As Propylenglycol-holdige peptidformuleringer hvilke er optimale til fremstilling og til anvendelse i injektionsindretninger
ATE517119T1 (de) 2003-12-03 2011-08-15 Novo Nordisk As Einzelketteninsulin
DE602004029496D1 (de) 2003-12-22 2010-11-18 Novo Nordisk As Offbehälter zur lagerung von pharmazeutischen flüssigkeiten
EP2033662B1 (en) 2004-01-21 2012-10-17 Novo Nordisk Health Care AG Transglutaminase mediated conjugation of peptides
PT1740154E (pt) * 2004-03-12 2009-09-11 Biodel Inc Composições de insulina com absorção melhorada
WO2006008238A1 (en) * 2004-07-16 2006-01-26 Novo Nordisk A/S Method for selective acylation
CN105801686B (zh) 2004-07-19 2020-04-07 比奥孔有限公司 胰岛素-低聚物共轭物、制剂及其用途
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
ES2435522T3 (es) * 2005-02-02 2013-12-20 Novo Nordisk A/S Derivados de insulina
ES2438145T3 (es) 2005-02-02 2014-01-16 Novo Nordisk A/S Nuevos derivados de insulina
WO2006125762A1 (en) * 2005-05-25 2006-11-30 Novo Nordisk A/S Stabilized polypeptide formulations
EP1888118B1 (en) 2005-05-25 2016-08-17 Novo Nordisk A/S Polypeptide formulations stabilized with ethylenediamine
EP1888104A2 (en) * 2005-05-26 2008-02-20 Novo Nordisk A/S Acylated insulin with high purity
ES2375929T3 (es) 2005-07-04 2012-03-07 High Point Pharmaceuticals, Llc Antagonistas del receptor histamina h3.
EP1910317B1 (en) 2005-07-20 2013-07-03 Eli Lilly And Company 1-amino linked compounds
ATE513921T1 (de) 2005-08-16 2011-07-15 Novo Nordisk As Verfahren zur herstellung reifer insulinpolypeptide
US7741281B2 (en) * 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
ES2393757T3 (es) 2005-11-17 2012-12-27 Eli Lilly & Company Antagonistas de receptor de glucagón, preparación y usos terapéuticos
PL1969004T3 (pl) 2005-12-28 2012-01-31 Novo Nordisk As Kompozycje zawierające acylowaną insulinę i cynk oraz sposób wytwarzania tych kompozycji
CA2637569C (en) 2006-01-18 2013-01-08 Yuhua Li Pharmaceutical compositions with enhanced stability
EP2256129B1 (en) 2006-02-27 2012-05-09 Novo Nordisk A/S Insulin derivatives
JP2009530242A (ja) * 2006-03-13 2009-08-27 ノボ・ノルデイスク・エー／エス アシル化単鎖インスリン
ES2397659T3 (es) 2006-03-15 2013-03-08 Novo Nordisk A/S Mezclas de amilina e insulina
KR101280333B1 (ko) 2006-03-28 2013-07-02 하이 포인트 파마슈티칼스, 엘엘씨 히스타민 ｈ３ 수용체 활성을 갖는 벤조티아졸
CN101432262B (zh) 2006-04-24 2011-06-01 伊莱利利公司 作为11-β-羟类固醇脱氢酶1的抑制剂的环己基取代的吡咯烷酮类
EP2386572B1 (en) 2006-05-09 2015-07-08 Novo Nordisk A/S Insulin derivative
CN101437849B (zh) * 2006-05-09 2015-09-30 诺沃-诺迪斯克有限公司 胰岛素衍生物
US8796205B2 (en) 2006-05-09 2014-08-05 Novo Nordisk A/S Insulin derivative
US7714025B2 (en) * 2006-05-10 2010-05-11 Arizona Biomedical Research Commission Modified chalcone compounds as antimitotic agents
KR20090040259A (ko) 2006-05-29 2009-04-23 하이 포인트 파마슈티칼스, 엘엘씨 3-(1,3-벤조디옥솔-5-일)-6-(4-시클로프로필피페라진-1-일)-피리다진, 그것의 염과 용매화합물 및 그것의 히스타민 ｈ3 수용체 안타고니스트로서의 용도
RU2456018C2 (ru) 2006-07-11 2012-07-20 КьюПиЭс, ЭлЭлСи Фармацевтические композиции для доставки пептидов с замедленным высвобождением
EP2049149B1 (en) 2006-07-31 2015-04-15 Novo Nordisk A/S Pegylated extended insulins
AU2007298919C1 (en) 2006-09-22 2014-02-06 Novo Nordisk A/S Protease resistant insulin analogues
WO2008037735A1 (en) 2006-09-27 2008-04-03 Novo Nordisk A/S Method for making maturated insulin polypeptides
WO2008049711A1 (en) * 2006-10-27 2008-05-02 Novo Nordisk A/S Peptide extended insulins
CN101674812B (zh) 2007-04-30 2013-12-11 诺沃-诺迪斯克有限公司 干燥蛋白组合物的方法、干燥的蛋白组合物和包含干燥的蛋白的药物组合物
MX2009012789A (es) 2007-06-01 2009-12-10 Novo Nordisk As Composiciones farmaceuticas no acuosas estables.
EP2514406A1 (en) 2007-06-01 2012-10-24 Novo Nordisk A/S Spontaneously dispersible preconcentrates including a peptide drug in a solid or semisolid carrier
EP2167032B1 (en) 2007-06-13 2019-08-07 Novo Nordisk A/S Pharmaceutical formulation comprising an insulin derivative
EP2178909B1 (en) 2007-08-13 2015-10-21 Novo Nordisk A/S Rapid acting insulin analogues
AU2008313248B2 (en) * 2007-10-16 2012-04-26 Biocon Limited An orally administerable solid pharmaceutical composition and a process thereof
EP2058330A1 (en) * 2007-11-08 2009-05-13 Novo Nordisk A/S Insulin derivative
US8710000B2 (en) 2007-11-08 2014-04-29 Novo Nordisk A/S Insulin derivative
JP5241849B2 (ja) 2007-11-16 2013-07-17 ノボ・ノルデイスク・エー／エス インスリン及びインスリン分泌性ペプチドを含む薬学的組成物
CN101951957A (zh) * 2008-01-04 2011-01-19 百达尔公司 胰岛素释放作为组织的葡萄糖水平的函数的胰岛素制剂
US9260502B2 (en) 2008-03-14 2016-02-16 Novo Nordisk A/S Protease-stabilized insulin analogues
KR101755434B1 (ko) 2008-03-18 2017-07-10 노보 노르디스크 에이/에스 프로테아제 안정화되고, 아실화된 인슐린 유사체
TWI451876B (zh) 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
RU2458989C1 (ru) 2008-08-07 2012-08-20 Байокон Лимитид Способ получения аналогов инсулина из их соответствующих предшественников (варианты)
CA2738615A1 (en) 2008-10-30 2010-05-06 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
JP2012509879A (ja) 2008-11-21 2012-04-26 ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー アダマンチルベンズアミド化合物
CA2750262C (en) 2009-01-28 2016-08-09 Smartcells, Inc. Conjugate based systems for controlled drug delivery
EP2391217A4 (en) 2009-01-28 2015-05-20 Smartcells Inc SYNTHETIC CONJUGATES AND USES THEREOF
US9060927B2 (en) * 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
CA2754950A1 (en) 2009-03-20 2010-09-23 Smartcells, Inc. Terminally-functionalized conjugates and uses thereof
US20120134977A1 (en) 2009-06-01 2012-05-31 Yeda Research And Development Co. Ltd. Prodrugs containing albumin binding probe
BR112012012945A2 (pt) 2009-11-25 2020-12-29 Arisgen Sa Composição de liberação mucosal, seu método de produção, complexo de peptídeo pré-formado, kit e uso de um agente ativo de peptídeo
EP2460527A1 (en) 2010-01-21 2012-06-06 Sanofi Pharmaceutical composition for treating a metabolic syndrome
AR081066A1 (es) * 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
US9981017B2 (en) 2010-04-02 2018-05-29 Hanmi Science Co., Ltd. Insulin conjugate using an immunoglobulin fragment
TW201141513A (en) 2010-04-14 2011-12-01 Sanofi Aventis Insulin-siRNA conjugates
ES2612468T3 (es) * 2010-05-10 2017-05-17 Novo Nordisk A/S Procedimiento para la preparación de complejos de insulina-zinc
EP2627670A2 (en) * 2010-10-15 2013-08-21 Novo Nordisk A/S Novel n-terminally modified insulin derivatives
DK2632478T3 (da) 2010-10-27 2019-10-07 Novo Nordisk As Behandling af diabetes melitus under anvendelse af insulinindsprøjtninger indgivet med varierende indsprøjtningsintervaller
WO2012087838A1 (en) 2010-12-22 2012-06-28 Baxter International Inc. Materials and methods for conjugating a water soluble fatty acid derivative to a protein
KR20140043709A (ko) 2011-01-20 2014-04-10 질랜드 파마 에이/에스 아실화 글루카곤 유사체와 인슐린 유사체의 조합
US10130684B2 (en) 2011-02-03 2018-11-20 Pharmedica Ltd. Oral dissolving films for insulin administration, for treating diabetes
EP2696897A2 (en) 2011-04-11 2014-02-19 Yeda Research and Development Co. Ltd. Albumin binding probes and drug conjugates thereof
EP2548570A1 (en) 2011-07-19 2013-01-23 Sanofi Pharmaceutical composition for treating a metabolic syndrome
CN102504022A (zh) * 2011-11-30 2012-06-20 苏州元基生物技术有限公司 含有保护赖氨酸的胰岛素原及使用其制备胰岛素的方法
WO2013086927A1 (zh) * 2011-12-15 2013-06-20 上海恒瑞医药有限公司 人胰岛素类似物及其酰化衍生物
ES2594303T3 (es) 2012-04-11 2016-12-19 Novo Nordisk A/S Formulaciones de insulina
JP6262206B2 (ja) 2012-05-01 2018-01-17 ノヴォ ノルディスク アー／エス 医薬組成物
WO2014088836A1 (en) 2012-12-03 2014-06-12 Merck Sharp & Dohme Corp. O-glycosylated carboxy terminal portion (ctp) peptide-based insulin and insulin analogues
WO2014177623A1 (en) 2013-04-30 2014-11-06 Novo Nordisk A/S Novel administration regime
JP6822839B2 (ja) 2013-09-13 2021-01-27 ザ・スクリップス・リサーチ・インスティテュート 修飾された治療剤、及びその組成物
PL3055325T3 (pl) * 2013-10-07 2018-06-29 Novo Nordisk A/S Nowa pochodna analogu insuliny
EP4212180A1 (en) 2013-12-18 2023-07-19 The Scripps Research Institute Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
AR099569A1 (es) 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
WO2015196174A1 (en) 2014-06-20 2015-12-23 Greene Howard E Infusion delivery devices and methods
CN107921098A (zh) 2015-06-17 2018-04-17 加州生物医学研究所 修饰的治疗剂及其组合物
MX2018002223A (es) 2015-08-25 2018-03-23 Novo Nordisk As Derivados de insulina novedosos y usos medicos de los mismos.
US10815287B2 (en) 2016-08-02 2020-10-27 Jiangsu Hengrui Medicine Co., Ltd. Acylated derivative of human insulin or analogue thereof
EP3329930A1 (en) 2016-12-05 2018-06-06 Nuritas Limited Pharmaceuctical compositions
ES2932498T3 (es) 2016-12-05 2023-01-20 Nuritas Ltd Composiciones que comprenden el péptido WKDEAGKPLVK
MY200748A (en) 2016-12-16 2024-01-13 Novo Nordisk As Insulin containing pharmaceutical compositions
CN118903386A (zh) 2017-08-24 2024-11-08 诺和诺德股份有限公司 Glp-1组合物及其用途
CN111406073A (zh) * 2017-09-29 2020-07-10 韩美药品株式会社 具有提高功效的持久性蛋白质缀合物
WO2019125879A2 (en) 2017-12-18 2019-06-27 Merck Sharp & Dohme Corp. Conjugate based systems for controlled insulin delivery
EP3727424A4 (en) 2017-12-18 2021-10-27 Merck Sharp & Dohme Corp. CONJUGATE-BASED SYSTEMS FOR CONTROLLED INSULIN DELIVERY
TW201934752A (zh) 2018-02-09 2019-09-01 大陸商江蘇恆瑞醫藥股份有限公司 一種密碼子優化的人胰島素類似物前體基因和信號肽基因
US20210198311A1 (en) 2018-05-24 2021-07-01 Jiangsu Hengrui Medicine Co., Ltd. Method for preparing precursor of recombinant human insulin or analogue thereof
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
KR102666154B1 (ko) 2018-08-08 2024-05-20 주식회사 대웅제약 지속형 인슐린 아날로그 및 그 복합체
MX2021006969A (es) 2018-12-11 2021-07-15 Sanofi Sa Ligante peptidico.
KR20200080747A (ko) 2018-12-27 2020-07-07 주식회사 폴루스 인슐린 전구체의 인슐린 효소 전환용 조성물 및 이를 이용하여 인슐린 전구체를 인슐린으로 전환하는 방법
KR20200080748A (ko) 2018-12-27 2020-07-07 주식회사 폴루스 음이온 교환 크로마토그래피를 이용한 인슐린 전구체의 정제방법
CN111909255A (zh) * 2019-05-10 2020-11-10 宁波鲲鹏生物科技有限公司 胰岛素衍生物及其制备方法
EP3996679B1 (en) 2019-07-12 2023-09-06 Novo Nordisk A/S High concentration insulin formulation
TW202434620A (zh) 2019-07-31 2024-09-01 美商美國禮來大藥廠 鬆弛素(relaxin)類似物及其使用方法
EP4073097B1 (en) 2019-12-11 2024-07-03 Novo Nordisk A/S Novel insulin analogues and uses thereof
KR20220121833A (ko) 2019-12-30 2022-09-01 간 앤 리 파마슈티칼스 컴퍼니, 리미티드 인슐린 유도체
EP4086277A4 (en) 2019-12-30 2024-02-14 Gan & Lee Pharmaceuticals Co., Ltd. LONG-ACTING GLP-1 COMPOUND
CN115135304A (zh) 2020-02-18 2022-09-30 诺和诺德股份有限公司 Glp-1组合物及其用途
IL296804A (en) 2020-03-31 2022-11-01 Protomer Tech Inc Conjugates for selective responsiveness to vicinal diols
TW202237188A (zh) 2020-11-19 2022-10-01 美商普羅托莫科技公司 芳族含硼化合物及胰島素類似物
AU2022289610A1 (en) 2021-06-09 2024-01-25 The Scripps Research Institute Long-acting dual gip/glp-1 peptide conjugates and methods of use
EP4180060A1 (en) 2021-11-15 2023-05-17 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
EP4299057A1 (en) 2022-06-30 2024-01-03 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
WO2023084118A1 (en) 2021-11-15 2023-05-19 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
WO2023143458A1 (zh) 2022-01-28 2023-08-03 甘李药业股份有限公司 酰化胰岛素
EP4299071A1 (en) 2022-07-01 2024-01-03 Adocia Compositions comprising a peptide or a protein and an acylated amino acid
WO2024051787A1 (zh) * 2022-09-09 2024-03-14 北京惠之衡生物科技有限公司 一种长效酰化胰岛素衍生物及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3823125A (en) * 1969-10-14 1974-07-09 American Home Prod N-aminoacyl-substituted insulins
US3950517A (en) * 1970-05-08 1976-04-13 National Research Development Corporation Insulin derivatives
GB1381273A (en) * 1971-01-28 1975-01-22 Nat Res Dev Insulin derivatives
GB1381274A (en) * 1971-01-28 1975-01-22 Nat Res Dev Insulin derivatives
US3907763A (en) * 1972-03-01 1975-09-23 Bayer Ag Insulin derivatives crosslinked by a dicarboxylic acid moiety
DK319780A (da) * 1980-07-24 1982-01-25 Forenede Bryggerier As Fremgangsmaade til enzymatisk udskiftning af b-30 aminosyren i insuliner
NL8201650A (nl) * 1982-04-21 1983-11-16 Akzo Nv Semisynthetische bereiding van humane insuline.
IL68769A (en) * 1983-05-23 1986-02-28 Hadassah Med Org Pharmaceutical compositions containing insulin for oral administration
US5008241A (en) * 1985-03-12 1991-04-16 Novo Nordisk A/S Novel insulin peptides
JPH01254699A (ja) * 1988-04-05 1989-10-11 Kodama Kk インスリン誘導体及びその用途
DK45590D0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1990-02-21 1990-02-21 Novo Nordisk As
DK155690D0 (da) * 1990-06-28 1990-06-28 Novo Nordisk As Nye peptider
WO1992001476A1 (en) * 1990-07-26 1992-02-06 University Of Iowa Research Foundation Novel drug delivery systems for proteins and peptides using albumin as a carrier molecule
US5336782A (en) * 1991-04-24 1994-08-09 Kuraray Co., Ltd. Long chain carboxylic acid imide ester

Also Published As

Publication number Publication date
BG100420A (bg) 1996-12-31
CA2171424A1 (en) 1995-03-23
US5750497A (en) 1998-05-12
FI961220A0 (fi) 1996-03-15
JP3014764B2 (ja) 2000-02-28
NO961070L (no) 1996-05-15
HU9600676D0 (en) 1996-05-28
NZ273285A (en) 1997-10-24
JPH09502867A (ja) 1997-03-25
IL110977A (en) 2000-06-29
AU7652094A (en) 1995-04-03
AU4846197A (en) 1998-02-19
NO961070D0 (no) 1996-03-15
CZ78996A3 (en) 1996-10-16
DE69428134D1 (de) 2001-10-04
SI0792290T1 (en) 2001-12-31
PL313444A1 (en) 1996-07-08
RO112873B1 (ro) 1998-01-30
EP1132404A3 (en) 2002-03-27
NL300160I2 (nl) 2005-07-01
BR9407508A (pt) 1997-01-07
IL110977A0 (en) 1994-11-28
PT792290E (pt) 2002-01-30
EP1132404A2 (en) 2001-09-12
AU682061B2 (en) 1997-09-18
NO2004006I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2008-02-04
CN1056618C (zh) 2000-09-20
NO2017041I1 (no) 2017-08-01
SK32496A3 (en) 1996-11-06
FI961220L (fi) 1996-05-14
DE122004000035I2 (de) 2009-08-06
UA45321C2 (uk) 2002-04-15
PL178466B1 (pl) 2000-05-31
WO1995007931A1 (en) 1995-03-23
JP2000060556A (ja) 2000-02-29
JP2002308899A (ja) 2002-10-23
FR04C0020I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2004-10-29
KR960704925A (ko) 1996-10-09
DE69428134T2 (de) 2002-05-02
SK282495B6 (sk) 2002-02-05
NL300160I1 (nl) 2004-12-01
DK0792290T3 (da) 2001-10-01
HU217684B (hu) 2000-03-28
BG61611B1 (bg) 1998-01-30
NO316944B1 (no) 2004-07-05
DE122004000035I1 (de) 2005-02-24
CZ287945B6 (cs) 2001-03-14
HUT75991A (en) 1997-05-28
CA2171424C (en) 2002-06-04
NO2004006I1 (no) 2004-10-11
KR100310122B1 (ko) 2002-04-24
FI117055B (fi) 2006-05-31
JP3917333B2 (ja) 2007-05-23
FR04C0020I2 (fr) 2005-05-27
CN1133598A (zh) 1996-10-16
RU2164520C2 (ru) 2001-03-27
EP0792290A1 (en) 1997-09-03
NO2017041I2 (no) 2018-11-19
EP0792290B1 (en) 2001-08-29
JP4060583B2 (ja) 2008-03-12
ATE204882T1 (de) 2001-09-15
ES2163451T3 (es) 2002-02-01

Similar Documents

Publication Publication Date Title
NO2017041I2 (no) Insulin detemir
RU96108249A (ru) Ацилированный инсулин
NZ330700A (en) B27, B28, B29 (B chain) insulin derivatives having a rapid onset of action
EP0837072A3 (en) Lys (B28) insulins. Human insulin analogues
EP0254516A3 (en) Novel peptides
PL322299A1 (en) Derivatives of insulin
CA2081659A1 (en) Recombinant human factor viii derivatives
ES526201A0 (es) Un procedimiento para preparar un peptido que tiene influencia sobre la funcion de la glandula pituitaria
CA2385857A1 (en) C peptide for improved preparation of insulin and insulin analogs
ES2144357A1 (es) Procedimiento para la obtencion del analogo de somatostatina octreotide.
IL94939A0 (en) Substitution analogues of magainin peptides
EP0911035A3 (en) Insoluble insulin compositions
ES316390A1 (es) Procedimiento para la obtencion de péptidos con efecto acth
HU911358D0 (en) Grf analogues
GR3015492T3 (en) ZNS-active hexapeptides with antiamnestic activity.
DK119391A (da) Humaninsulinanaloger